Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Problems With 340B? GAO Is Now Gathering Information From Drug Manufacturers

This article was originally published in The Pink Sheet Daily

Executive Summary

The Government Accountability Office has begun interviewing pharmaceutical manufacturers about their experiences with the 340B drug discount program in preparation for a report mandated by the Affordable Care Act.

You may also be interested in...



GAO And Legislators Pushing HHS For Stronger 340B Oversight

The Government Accountability Office is proposing several recommendations to strengthen oversight of the 340B drug discount program, but says the HHS Health Resources and Services Administration wants to take other measures that GAO believes are insufficient.

GAO And Legislators Pushing HHS For Stronger 340B Oversight

The Government Accountability Office is proposing several recommendations to strengthen oversight of the 340B drug discount program, but says the HHS Health Resources and Services Administration wants to take other measures that GAO believes are insufficient.

Rx Pricing At The High Court: Justices Friendlier To Enforcement From States Than 340B Entities

U.S. Supreme Court justices’ skepticism over the right of 340B entities to sue pharmaceutical companies for overcharges does not appear to extend to states’ ability to challenge drug prices reported under Medicaid.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel